Impact of febrile neutropenia and colony stimulating factor use on chemotherapy delivery in patients with lymphoma: Results from the INC-EU prospective observational European neutropenia study.

被引：0
|
作者：
Pettengell, Ruth
Bosly, Andre
Szucs, Thomas D.
Jackisch, Christian
Leonard, Robert
Paridaens, Robert
Constenla, Manuel
Schwenkglenks, Matthias
机构：
来源：
BLOOD | 2006年 / 108卷 / 11期
关键词：
D O I：
10.1182/blood.V108.11.2444.2444
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2444
引用
收藏
页码：692A / 692A
页数：1
相关论文
共 50 条
  • [21] Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: A systematic review
    Kuderer, Nicole M.
    Dale, David C.
    Crawford, Jeffrey
    Lyman, Gary H.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (21) : 3158 - 3167
  • [22] Real-World Impact of a Decision Support Tool on Colony-Stimulating Factor Use and Chemotherapy-Induced Febrile Neutropenia Among Patients With Breast Cancer
    Agiro, Abiy
    DeVries, Andrea
    Malin, Jennifer
    Fisch, Michael J.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2018, 16 (02): : 162 - 169
  • [23] Evaluating the Prognostic Role of Monocytopenia in Chemotherapy-Induced Febrile Neutropenia Patients Treated with Granulocyte Colony-Stimulating Factor
    Alshari, Osama
    Al Zu'bi, Yazan O.
    Al Sharie, Ahmed H.
    Wafai, Farouk H.
    Aleshawi, Abdelwahab J.
    Atawneh, Farah H.
    Obeidat, Hasan A.
    Daoud, Majd N.
    Khrais, Mohammad Z.
    Albals, Dima
    Tubaishat, Faize
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2021, 17 : 963 - 973
  • [24] Use of colony-stimulating factor primary prophylaxis and incidence of febrile neutropenia from 2010 to 2016: a longitudinal assessment
    Weycker, Derek
    Bensink, Mark
    Lonshteyn, Alexander
    Doroff, Robin
    Chandler, David
    CURRENT MEDICAL RESEARCH AND OPINION, 2019, 35 (06) : 1073 - 1080
  • [25] Burden of Chemotherapy-Induced Febrile Neutropenia Hospitalizations in US Clinical Practice, by Use and Patterns of Prophylaxis with Colony-Stimulating Factor
    Derek Weycker
    Xiaoyan Li
    Spiros Tzivelekis
    Mark Atwood
    Jacob Garcia
    Yanli Li
    Maureen Reiner
    Gary H. Lyman
    Supportive Care in Cancer, 2017, 25 : 439 - 447
  • [26] Burden of Chemotherapy-Induced Febrile Neutropenia Hospitalizations in US Clinical Practice, by Use and Patterns of Prophylaxis with Colony-Stimulating Factor
    Weycker, Derek
    Li, Xiaoyan
    Tzivelekis, Spiros
    Atwood, Mark
    Garcia, Jacob
    Li, Yanli
    Reiner, Maureen
    Lyman, Gary H.
    SUPPORTIVE CARE IN CANCER, 2017, 25 (02) : 439 - 447
  • [27] XM02, the first granulocyte colony-stimulating factor biosimilar, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with non-Hodgkin lymphoma receiving chemotherapy
    Engert, A.
    Griskevicius, L.
    Zyuzgin, Y.
    Lubenau, H.
    Del Giglio, A.
    LEUKEMIA & LYMPHOMA, 2009, 50 (03) : 374 - 379
  • [28] Review of practice patterns of primary granulocyte-colony stimulating factor prophylaxis and impact on febrile neutropenia rate and chemotherapy delivery in patients with early breast cancer treated with modern adjuvant chemotherapy.
    Mates, Mihaela
    Hopman, Wilma
    Altwairgi, Abdullah Khalaf
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [29] Study Inclusion Criteria and Presentation of Results in a Meta-Analysis of Granulocyte Colony-Stimulating Factor for Prevention of Febrile Neutropenia
    Lathia, Nina
    Isogai, Pierre K.
    Cheung, Matthew C.
    Mittmann, Nicole
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (36) : E762 - E763
  • [30] Comparison of low-dose versus standard-dose colony stimulating factor in patients with chemotherapy-induced febrile neutropenia
    Burney, IA
    Salam, A
    Jat, AA
    Iqbal, MP
    Siddiqui, T
    Khan, MA
    Smego, RA
    ONCOLOGY, 2003, 65 (03) : 283 - 284
12345